HOME ·

SUNSHINE PHARMA

SUNSHINE PHARMA (06887.HK): Insulin Degludec/Aspart Injection Wins NMPA Approval
Tags：
NewTimeSpaceSUNSHINE PHARMA06887.HK
2026-10-08
SUNSHINE PHARMA (06887.HK): Files CSRC Filing for H-share Full Circulation; 38.9m Domestic Shares to Convert
Tags：
NewTimeSpaceSUNSHINE PHARMA06887.HK
2026-09-23
SUNSHINE PHARMA (06887.HK): Compliance Adviser Changed, Yin Leung Capital (Asia Pacific) Appointed as New Adviser
Tags：
SUNSHINE PHARMA06887.HKcompliance adviser
2026-08-31
Sunshine Lake Pharma (06887.HK): Insulin Degludec Injection Receives NMPA Marketing Approval; Domestic Insulin Portfolio Expands to 6 Products
Tags：
SUNSHINE PHARMA06887.HK
2026-07-30
SUNSHINE PHARMA (06887.HK): Controlling Shareholder & Non-executive Director Zhang Yushuai Proposes to Increase Holdings by HK$300 Million – HK$600 Million
Tags：
SUNSHINE PHARMA06887.HKShare IncreaseShare Repurchase
2026-07-21
SUNSHINE PHARMA(06887.HK) closed 23.71% lower on Jul 17, leading declines in the Hang Seng Pharmaceuticals & Biotechnology Sector
Tags：
SUNSHINE PHARMA06887.HKNewTimeSpace
2026-07-17